Skip to content

US · NVCT · BIOTECHNOLOGY

Nuvectis Pharma, Inc. (NVCT) intrinsic value and stock valuation

$19.39as of 2026-11-21 · Mkt cap 511.09M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nuvectis Pharma, Inc. DCF and intrinsic value

InvestorsCraft values NVCT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NVCT’s statements →

Nuvectis Pharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Fort Lee, NJ 07024 nuvectis.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-26.44M
20202025
Free cash flow
-$-16.01M
20202025
Total equity
$18.4M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-27.57M-$-19.85M-$-22.9M-$-19.23M-$-12.89M
Net income-$-26.44M-$-19M-$-22.26M-$-19.09M-$-12.89M
EPSd-$-1.21M-$-1.11M-$-1.43M-$-1.51M-$-1.01M
Operating cash flow-$-16.01M-$-12.25M-$-15.95M-$-13.56M-$-9.5M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-16.01M-$-12.25M-$-15.95M-$-13.56M-$-9.5M
Total assets$31.7M$18.6M$19.2M$20.4M$6.66M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-31.63M-$-18.53M-$-19.13M-$-19.99M-$-5.74M
Total equity$18.4M$9.71M$12.2M$14.2M-$-11.01M
Cash and short-term investments$31.6M$18.5M$19.1M$20M$5.74M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$18.2M$12.9M$15.4M$13.2M$9.54M
Selling, general and administrative expenses$9.42M$6.93M$7.52M$6.01M$3.35M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$27.6M$19.9M$22.9M$19.2M$12.9M
Cost and expenses$27.6M$19.9M$22.9M$19.2M$12.9M
Interest income$1.13M$850K$640K$150K$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-26.44M-$-19M-$-22.26M-$-19.09M-$-12.89M
Operating income-$-27.57M-$-19.85M-$-22.9M-$-19.23M-$-12.89M
Total other income/expenses, net$1.13M$850K$640K$150K$0.00
Income before tax-$-26.44M-$-19M-$-22.26M-$-19.09M-$-12.89M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-26.44M-$-19M-$-22.26M-$-19.09M-$-12.89M
Weighted average shares outstanding$21.8M$17.1M$15.6M$12.7M$12.7M
Weighted average diluted shares outstanding$21.8M$17.1M$15.6M$12.7M$12.7M
Balance sheet
20252024202320222021
Cash and short-term investments$31.6M$18.5M$19.1M$20M$5.74M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$31.7M$18.6M$19.2M$20.4M$5.83M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$0.00$0.00$820K
Total assets$31.7M$18.6M$19.2M$20.4M$6.66M
Accounts payable$6.27M$2.5M$2.77M$2.91M$1.06M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$13.3M$8.89M$6.98M$6.19M$2.42M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$15.3M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$13.3M$8.89M$6.98M$6.19M$17.7M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-99.69M-$-73.25M-$-54.24M-$-31.98M-$-12.9M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$18.4M$9.71M$12.2M$14.2M-$-11.01M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-31.63M-$-18.53M-$-19.13M-$-19.99M-$-5.74M
Cash flow statement
20252024202320222021
Net income-$-26.44M-$-19M-$-22.26M-$-19.09M-$-12.89M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$6.03M$4.86M$4.71M$1.71M$1.89M
Change in working capital$4.4M$1.9M$1.6M$3.82M$1.49M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$3.78M-$-270K-$-140K$1.85M$0.00
Net cash provided by operating activities-$-16.01M-$-12.25M-$-15.95M-$-13.56M-$-9.5M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$31.2M$12M$5.29M$31.9M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$29.1M$11.7M$15.1M$27.8M$15.3M
Net change in cash$13.1M-$-590K-$-870K$14.3M$5.74M
Cash at end of period$31.6M$18.5M$19.1M$20M$5.74M
Operating cash flow-$-16.01M-$-12.25M-$-15.95M-$-13.56M-$-9.5M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-16.01M-$-12.25M-$-15.95M-$-13.56M-$-9.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nuvectis Pharma, Inc.

        Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

        CEO
        Ron Bentsur
        Employees
        13
        Beta
        -0.25

        Explore

        Frequently asked questions

        What is the intrinsic value of Nuvectis Pharma, Inc. (NVCT)?

        InvestorsCraft does not currently publish an intrinsic value for NVCT. How the IC value is calculated.

        Is NVCT undervalued?

        InvestorsCraft does not publish an undervaluation signal for NVCT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.